Voorberg Angelique N, Oosterhaven Jart A F, Wijdh Robert H J, de Bruin-Weller Marjolein S, Schuttelaar Marie L A
UMC Groningen, afd. Dermatologie.
Contact: A.N. Voorberg (
Ned Tijdschr Geneeskd. 2019 Mar 21;163:D3227.
Dupilumab, the first registered biological for the treatment of atopic dermatitis, frequently causes adverse ocular events. These often take the form of mild conjunctivitis or blepharoconjunctivitis, however, more serious adverse ocular events have also been reported, including limbal stem cell insufficiency.
A 56-year-old man was treated with dupilumab for severe atopic dermatitis. His eczema improved greatly, but he developed bilateral conjunctivitis with limbal stem cell insufficiency in his right eye. After discontinuation of dupilumab, the eye symptoms gradually disappeared. After three months no conjunctivitis or limbal stem cell insufficiency was observed on ophthalmological examination.
Adverse ocular events are often seen in the treatment of atopic dermatitis with dupilumab. Caution is advised if severe adverse events occur. Therefore, it is important to identify the underlying pathophysiological mechanism of these adverse events.
度普利尤单抗是首个获批用于治疗特应性皮炎的生物制剂，常引发眼部不良事件。这些事件通常表现为轻度结膜炎或睑结膜炎，然而，也有更严重的眼部不良事件被报道，包括角膜缘干细胞功能不全。
一名56岁男性因重度特应性皮炎接受度普利尤单抗治疗。他的湿疹有显著改善，但出现了双侧结膜炎，右眼伴有角膜缘干细胞功能不全。停用度普利尤单抗后，眼部症状逐渐消失。三个月后眼科检查未发现结膜炎或角膜缘干细胞功能不全。
在使用度普利尤单抗治疗特应性皮炎时经常会出现眼部不良事件。如果发生严重不良事件，建议谨慎处理。因此，明确这些不良事件的潜在病理生理机制很重要。
